Skip to content
Esta página está disponible en españolCambiar →
GestorLensSign up

Abivax (ABVX): which funds own it

Health Care →Data as of Jun 30, 2026 (Q2 2026) · updated on Nov 5, 2026

A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.

Follow ABVX for free
Share

Sections with a free account

28 concentrated managers hold it (+1 vs last quarter) with a median weight of 4.3%.

Who owns Abivax?

Abivax trades in the U.S. through ADRs, certificates that represent shares of a non-U.S. company. Form 13F counts ADRs while the company reports ordinary shares, so we do not compute percentages. Holders reporting more than 5% of the ordinary shares to the SEC (Schedules 13D/13G): Chen Yu, 7.0% (13G/A filed Aug 14, 2026) and Raymond Debbane, 6.0% (13G/A filed Aug 13, 2026). As of Jun 30, 2026, the largest ADR holders reported on Form 13F were TCG Crossover Management (6.0 million ADRs), Darwin Global Management (3.6 million ADRs) and Helikon Investments (2.8 million ADRs).

Which institutions hold the most Abivax shares?

Per Form 13F filings as of Jun 30, 2026, in ADRs:

  1. 1. TCG Crossover Management: 6.0 million ADRs
  2. 2. Darwin Global Management: 3.6 million ADRs
  3. 3. Helikon Investments: 2.8 million ADRs
  4. 4. Vestal Point Capital: 2.3 million ADRs
  5. 5. Jupiter Topco: 1.9 million ADRs
  6. 6. UBS Group: 1.8 million ADRs
  7. 7. ADAR1 Capital Management: 1.8 million ADRs
  8. 8. Caligan Partners: 1.6 million ADRs
  9. 9. Citadel Advisors: 1.4 million ADRs
  10. 10. Morgan Stanley: 1.4 million ADRs

Sources:13G/A by Chen Yu (Aug 14, 2026) ↗13G/A by Raymond Debbane (Aug 13, 2026) ↗All of the company's proxy statements on EDGAR ↗

We hold 13D and 13G filings made since Dec 23, 2024: a holder above 5% that has not filed since then does not appear here.

Concentrated managers
28
All 13F: 305
Consensus
59/100
across 28 concentrated managersRanks by accumulation, portfolio weight and number of managers; it does not say more are buying than selling.
Price at Jun 30, 2026 (per 13F)
$133.26
+19.7% in the quarter · reported value ÷ shares, not the quote · See current quote ↗

Quarter flow (concentrated managers)

Change in managers (27 → 28): 6 opened · 6 exited · 1 more with no comparable data = +1

“No comparable data”: managers whose previous-quarter portfolio we cannot compare (first 13F, or they did not file that quarter), plus spin-offs and corporate exits (mergers, delistings). They change the count without being a clean buy or sale. It is a net figure: “more” when more of them enter the count than leave it, “fewer” when it is the other way round. Here: 1 entered with no comparable quarter.

Net flow in the quarter: +$423M (+3.2 M shares) · bought $797M and sold $374MShares concentrated managers added minus those they cut, valued at the 13F quarter-end implied price, not each trade's price. It is a different measure from the change in managers: the two can have opposite signs.

The set of concentrated managers changed between quarters: with the set as it was then, 26 held it last quarter (the chart point); with today's set, 27 (the base for the change).

Concentrated managers holding it

Up to 15, sorted by position value. The percentage is the weight in each manager's portfolio.

Other relevant holders

Filers with $100M or more in the stock that do not count as concentrated managers because of their type: they are left out of the counts, the consensus and the accumulation.

Largest holders of ABVX (all 13F filers)

The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.

Insiders (Form 4)

Officers and directors who bought (6 m)
no data
Amount (6 m)
no data
CEO/CFO bought (12 m)
No

Open-market purchases, excluding 10b5-1 plans. Officers and directors only; joint filers of the same purchase count as one. 10% owners with no role are shown separately. 0 = nobody bought; “no data” = we do not have its Form 4 filings.

Each of the company's Form 4 filings, on EDGAR ↗Latest trades, with date and filing →

Above 5% (13D/13G)

Disclosed stakes, with their amendments. A filing is not always a purchase: there are also reductions and changes of filing entity.

This list may be incomplete: we hold 13D and 13G filings made since Dec 23, 2024. A holder above 5% that has not filed anything since then is not shown here.

  • Chen Yu7%13G · amendmentfiling ↗Event: Jun 30, 2026 · filed: Aug 14, 2026
  • Raymond Debbane6%13G · amendmentfiling ↗Event: Jun 30, 2026 · filed: Aug 13, 2026
  • Sofinnova Crossover I SLP4.3%(fell below 5%)13D · amendmentfiling ↗Event: Jul 2, 2026 · filed: Jul 6, 2026

Above 5% over time (13D/13G)

Each holder with its filings in order. History since December 2024.

This company filed no 8-K forms in the last year. Foreign companies listed in the US (ADRs) report material events on forms 6-K and 20-F, and ETFs and funds do not file 8-Ks. If it is a foreign company listed in the US through ADRs (American Depositary Receipts), what trades are bank-issued certificates that represent shares from its home market. See its filings on EDGAR ↗

Other Health Care stocks in managers' portfolios

Same sector and a similar number of concentrated managers holding them. It is a list to keep exploring, not a recommendation.

All of Health Care →

Follow ABVX for free

If someone reports a 5%+ stake, we email you (if you turn it on). And when you come back, see whether concentrated managers got in or out. No credit card.

Follow ABVX